Search company, investor...

Compare Celator Pharmaceuticals vs Alaunos Therapeutics

Customers evaluate the quality of Celator Pharmaceuticals's products using the following success metrics.

Overview

Celator Pharmaceuticals is 24 yrs old and is based in United States.

Celator Pharmaceuticals is a pharmaceutical company developing new and effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents an approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory.

Alaunos Therapeutics is 21 yrs old and is based in United States.

Alaunos Therapeutics (NASDAQ: TCRT) is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for patient treatment. Alaunos Therapeutics was formerly known as Alaunos Therapeutics. It was founded in 2003 and is based in Boston, Massachusetts.

Country

Demo Video

Demo not available because Celator Pharmaceuticals has not claimed their profile.

Work for Celator Pharmaceuticals? Show off your product.

Demo not available because Alaunos Therapeutics has not claimed their profile.

Work for Alaunos Therapeutics? Show off your product.

Leadership

Scott T Jackson (Chief Executive Officer)

See all 5 people

Jonathan Lewis (Founder)

See all 5 people

Funding

Alaunos Therapeutics last raised $30.88M on 2/9/2007.

Investors

Jazz Pharmaceuticals, Hercules Capital

See all 5 investors

Millennium Management, Medical Strategy

See all 5 investors

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Celator Pharmaceuticals has not claimed their profile.

Work for Celator Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Celator Pharmaceuticals?

Claim your profile now.

Information not available because Alaunos Therapeutics has not claimed their profile.

Work for Alaunos Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Alaunos Therapeutics?

Claim your profile now.